var data={"title":"Dexmethylphenidate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dexmethylphenidate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6001?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dexmethylphenidate-drug-information\" class=\"drug drug_general\">see &quot;Dexmethylphenidate: Drug information&quot;</a> and <a href=\"topic.htm?path=dexmethylphenidate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dexmethylphenidate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708694\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Drug dependence:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Give dexmethylphenidate cautiously to patients with a history of drug dependence or alcoholism. Long-term abusive use can lead to marked tolerance and psychological dependence with varying degrees of abnormal behavior. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during drug withdrawal from abusive use because severe depression may occur. Withdrawal following long-term therapeutic use may unmask symptoms of the underlying disorder that may require follow-up.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158416\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Focalin;</li>\n      <li>Focalin XR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1008289\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Central Nervous System Stimulant</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1008319\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=dexmethylphenidate-drug-information\" class=\"drug drug_general\">see &quot;Dexmethylphenidate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Reduce dose or discontinue in patients with paradoxical aggravation of symptoms or other adverse events. Discontinue if no improvement is seen after appropriate dosage adjustment over a 1-month period of time.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children and Adolescents:<b></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Attention-deficit/hyperactivity disorder: </b> Children &ge;6 years and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Patients not currently taking methylphenidate: </b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immediate release: Initial: 2.5 mg twice daily; doses should be taken at least 4 hours apart; dosage may be adjusted in increments of 2.5 to 5 mg at weekly intervals; maximum daily dose: 20 mg/<b>day</b> (manufacturer's labeling); some experts recommend maximum daily dose: 50 mg/<b>day</b> (Dopheide 2009; Pliszka 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Extended release: Initial: 5 mg once daily; dosage may be adjusted in increments of 5 mg/day at weekly intervals; maximum daily dose: 30 mg/<b>day</b> (manufacturer's labeling); some experts recommend maximum daily dose: 50 mg/<b>day</b> (Dopheide 2009; Pliszka 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Conversion to dexmethylphenidate from methylphenidate: </b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immediate release: Initial: Half the total daily dose of racemic methylphenidate; maximum daily dexmethylphenidate dose: 20 mg/<b>day</b> (manufacturer's labeling); some experts recommend maximum daily dose: 50 mg/<b>day</b> (Dopheide 2009; Pliszka 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Extended release: Initial: Half the total daily dose of racemic methylphenidate; maximum daily dexmethylphenidate dose: 30 mg/<b>day</b> (manufacturer's labeling); some experts recommend maximum daily dose: 50 mg/<b>day</b> (Dopheide 2009; Pliszka 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Conversion from dexmethylphenidate immediate release to dexmethylphenidate extended release:</b> When changing from Focalin tablets to Focalin XR capsules, switch to the same daily dose using Focalin XR; maximum daily dose: 30 mg/<b>day</b> (manufacturer's labeling); some experts recommend maximum daily dose: 50 mg/<b>day</b> (Dopheide 2009; Pliszka 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: <b>Attention-deficit/hyperactivity disorder:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Patients not currently taking methylphenidate: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: Initial: 2.5 mg twice daily; dosage may be adjusted in increments of 2.5 to 5 mg at weekly intervals; maximum daily dose: 20 mg/<b>day</b>; doses should be taken at least 4 hours apart</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: Initial: 10 mg once daily; dosage may be adjusted in increments of 10 mg/<b>day</b> at weekly intervals; maximum daily dose: 40 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Conversion to dexmethylphenidate from methylphenidate: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: Initial: Half the total daily dose of racemic methylphenidate; maximum daily dexmethylphenidate dose: 20 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: Initial: Half the total daily dose of racemic methylphenidate; maximum daily dexmethylphenidate dose: 40 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Conversion from dexmethylphenidate immediate release to dexmethylphenidate extended release:</b> When changing from Focalin tablets to Focalin XR capsules, switch to the same daily dose using Focalin XR; maximum daily dose: 40 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in renal impairment: </b>Children &ge;6 years, Adolescent, and Adults: There are no dosage adjustments provided in the manufacturer's labeling; however, since very little unchanged drug is eliminated in the urine, dosage adjustment in renal impairment is not expected to be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in hepatic impairment:</b> Children &ge;6 years, Adolescents, and Adults: No dosage adjustments provided in the manufacturer's labeling (not studied); use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158399\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Focalin XR: 5 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Focalin XR: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Focalin XR: 15 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Focalin XR: 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Focalin XR: 25 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Focalin XR: 30 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Focalin XR: 35 mg, 40 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Focalin: 2.5 mg, 5 mg, 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg, 5 mg, 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158384\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158431\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874426\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Focalin: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021278s023lbl.pdf&amp;token=wirABH654EPx9rH5vjspzYGgnvPKRaIZnQH7WzBjgt4YhDV2GaSAQFq1gmZYkbziIs+eCgV9uZjw3mpE1UoDCeNtuaxG3VDv9p6HJlTMxN4=&amp;TOPIC_ID=13010\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021278s023lbl.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Focalin XR: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf#page=17&amp;token=OJNu0vrkQJszxJeDYG95GcwUKlZcMDBM7QJfvJBYXsHPFZQAURjonLZXjTOTIfA2pc5pPewgvV4eEzu31bCOaZntoQdLwPo0pt59ieU7xzvf8YdLR+7X9eWJ9vaS63fO&amp;TOPIC_ID=13010\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf#page=17</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1008323\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: Twice daily dosing should be administered at least 4 hours apart; may be taken with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: Administer once daily in the morning. Do not crush, chew, or divide capsule; swallow whole. Capsule may be opened and contents sprinkled over a spoonful of applesauce; consume immediately and entirely; do not store for future use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158412\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light and moisture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1008290\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of attention-deficit/hyperactivity disorder (ADHD) (FDA approved in ages &ge;6 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5707763\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dexmethylphenidate may be confused with methadone</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Focalin may be confused with Focalgin-B, Folotyn</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158434\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Also refer to Methylphenidate for adverse effects seen with other methylphenidate products.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, depression (children and adolescents), dizziness (adults), emotional lability (children and adolescents), headache (more common in adults), insomnia (children and adolescents), irritability (children and adolescents), jitteriness (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus (children and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain (children and adolescents), anorexia (children and adolescents), decreased appetite (children and adolescents), dyspepsia, nausea (children and adolescents), vomiting (children and adolescents), xerostomia (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Nasal congestion (children and adolescents), pharyngolaryngeal pain (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (children and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, hypersensitivity reactions, peripheral vascular disease, Raynaud phenomenon, rhabdomyolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158404\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Marked anxiety, tension, and agitation; hypersensitivity to methylphenidate or any component of the formulation; glaucoma; motor tics; family history or diagnosis of Tourette syndrome; concurrent use with or within 14 days following discontinuation with monoamine oxidase inhibitor (MAOI) therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158388\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;\t Cardiovascular events: CNS stimulant use has been associated with serious cardiovascular events including sudden death in patients with preexisting structural cardiac abnormalities or other serious heart problems (sudden death in children and adolescents; sudden death, stroke, and MI in adults). These products should be avoided in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease (adults), or other serious cardiac problems that could increase the risk of sudden death that these conditions alone carry. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy. Patients who develop exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease should be evaluated promptly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;\t Hypersensitivity reactions: Hypersensitivity reactions including angioedema and anaphylactic reactions have been observed in patients treated with methylphenidate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;\t Peripheral vasculopathy: Stimulants are associated with peripheral vasculopathy, including Raynaud&rsquo;s phenomenon; signs/symptoms are usually mild and intermittent, and generally improve with dose reduction or discontinuation. Digital ulceration and/or soft tissue breakdown have been observed rarely; monitor for digital changes during therapy and seek further evaluation (eg, rheumatology) if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Priapism: Prolonged and painful erections (priapism), sometimes requiring surgical intervention, have been reported (rarely) with methylphenidate and atomoxetine use in pediatric and adult patients. Priapism has been reported to develop after some time on the drug, often subsequent to an increase in dose but also during a period of drug withdrawal (drug holidays or discontinuation). Patients with certain hematological dyscrasias (eg, sickle cell disease), malignancies, perineal trauma, or concomitant use of alcohol, illicit drugs, or other medications associated with priapism may be at increased risk. Patients who develop abnormally sustained or frequent and painful erections should discontinue therapy and seek immediate medical attention. An emergent urological consultation should be obtained in severe cases. Priapism has been associated with different dosage forms and products; it is not known if rechallenge with a different formulation will risk recurrence. Avoidance of stimulants and atomoxetine may be preferred in patients with severe cases that were slow to resolve and/or required detumescence (Eiland 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull;\t Tourette syndrome/tics: Use with caution in patients with Tourette syndrome or other tic disorders. Stimulants may exacerbate tics (motor and phonic) and Tourette syndrome; however, evidence demonstrating increased tics is limited. Evaluate for tics and Tourette syndrome prior to therapy initiation (AACAP [Pliszka 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;\t Visual disturbance: Difficulty in accommodation and blurred vision has been reported with the use of stimulants.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Abuse potential: <b>[US Boxed Warning]: Use with caution in patients with a history of alcohol or drug dependence.   Chronic abusive use can lead to marked tolerance and psychological dependence with varying degrees of abnormal behaviors. Frank psychotic episodes can occur, especially with parenteral abuse.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypertension: CNS stimulants may increase heart rate (mean increase: 3 to 6 bpm) and blood pressure (mean increase: 2 to 4 mm Hg). Use with caution in patients with hypertension and other cardiovascular conditions (eg, heart failure, recent myocardial infarction, ventricular arrhythmia) that might be exacerbated by increases in blood pressure or heart rate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;\t Psychiatric disorders: Use with caution in patients with preexisting psychosis; stimulants may exacerbate symptoms of behavior and thought disorder. Use with caution in patients with bipolar disorder; stimulants may induce mixed/manic episodes. New onset psychosis or mania may occur in children or adolescents with stimulant use. Patients presenting with depressive symptoms should be screened for bipolar disorder, including details regarding family history of suicide, bipolar disorder, and depression. Consider discontinuation if such symptoms (eg, delusional thinking, hallucinations, or mania) occur. May be associated with aggressive behavior or hostility (causal relationship not established); monitor for development or worsening of these behaviors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;\t Seizure disorder: Limited information exists regarding amphetamine use in seizure disorder (Cortese 2013). Use with caution in patients with a history of seizure disorder; may lower seizure threshold leading to new onset or breakthrough seizure activity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;\t Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Appetite suppression may occur, particularly in children. Use of stimulants has been associated with weight loss and slowing of growth rate; monitor growth rate and weight during treatment. Treatment interruption may be necessary in patients who are not increasing in height or gaining weight as expected.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Discontinuation of therapy: Abrupt discontinuation following high doses or for prolonged periods may result in symptoms of withdrawal including severe depression.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25855841\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Serious cardiovascular events, including sudden death, may occur in patients with preexisting structural cardiac abnormalities or other serious heart problems. Sudden death has been reported in children and adolescents; sudden death, stroke, and MI have been reported in adults. Avoid the use of CNS stimulants in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that could place patients at an increased risk to the sympathomimetic effects of a stimulant drug. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy. The American Heart Association recommends that all children diagnosed with ADHD who may be candidates for medication, such as dexmethylphenidate, should have a thorough cardiovascular assessment prior to initiation of therapy. This assessment should include a combination of medical history, family history, and physical examination focusing on cardiovascular disease risk factors. An ECG is not mandatory but should be considered. <b>Note:</b> ECG abnormalities and four cases of sudden cardiac death have been reported in children receiving clonidine with methylphenidate; this problem may potentially occur with dexmethylphenidate; consider ECG monitoring and reduction of dexmethylphenidate dose when used concurrently with clonidine.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\"> If a child displays symptoms of cardiovascular disease, including chest pain, dyspnea, or fainting, parents should seek immediate medical care for the child. In a recent retrospective study on the possible association between stimulant medication use and sudden death in children, 564 previously healthy children who died suddenly in motor vehicle accidents were compared to a group of 564 previously healthy children who died suddenly. Two of the 564 (0.4%) children in motor vehicle accidents were taking stimulant medications compared to 10 of 564 (1.8%) children who died suddenly. While the authors of this study conclude there may be an association between stimulant use and sudden death in children, there were a number of limitations to the study and the FDA cannot conclude this information impacts the overall risk:benefit profile of these medications (Gould 2009). In a large retrospective cohort study involving 1,200,438 children and young adults (aged 2 to 24 years), none of the currently available stimulant medications or atomoxetine were shown to increase the risk of serious cardiovascular events (ie, acute MI, sudden cardiac death, or stroke) in current (adjusted hazard ratio: 0.75; 95% CI: 0.31 to 1.85) or former (adjusted hazard ratio: 1.03; 95% CI: 0.57 to 1.89) users compared to nonusers. It should be noted that due to the upper limit of the 95% CI, the study could not rule out a doubling of the risk, albeit low (Cooper 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Stimulant  medications may increase blood pressure (average increase: 2 to 4 mm Hg) and heart rate (average increase: 3 to 6 bpm); some patients may experience greater increases. Long-term effects in pediatric patients have not been determined. Use of stimulants in children has been associated with growth suppression; monitor growth; treatment interruption may be needed. Appetite suppression may occur; monitor weight during therapy, particularly in children. May exacerbate motor and phonic tics and Tourette syndrome. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Evaluation of the effect of stimulants on growth in ADHD diagnosed children &lt;12 years receiving treatment for at least 3 years with stimulants has shown decreased height and weight changes over time compared to age matched control; height: 4.7 to 5.5 cm/year compared to 6.3 cm/year and 2.1 to 3.3 kg/year compared to 4.4 kg/year (Poulton 2016). In pediatric patients 8 to 17 years actively treated with stimulants, significant reductions in total femoral, femoral neck, and lumbar bone mineral density (BMD) were observed compared to matched unmedicated cohorts; also reported were significantly more subjects in the stimulant-treated group with BMD measurements in the osteopenic range compared to matched cohorts (38.3% to 21.6%) (Howard 2015). A longitudinal cohort-controlled trial reported no different in peak height velocity and final adult height in subjects with ADHD and/or treated with stimulants (Harstad 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299158\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158392\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13010&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acebrophylline: May enhance the stimulatory effect of CNS Stimulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Dexmethylphenidate may increase the serum concentration of Fosphenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May increase the absorption of Dexmethylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: Dexmethylphenidate may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Dexmethylphenidate.<b> Exceptions: </b>Tedizolid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: Dexmethylphenidate may increase the serum concentration of PHENobarbital. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Dexmethylphenidate may increase the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: Dexmethylphenidate may increase serum concentrations of the active metabolite(s) of Primidone. Specifically, phenobarbital concentrations could become elevated. Dexmethylphenidate may increase the serum concentration of Primidone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: Dexmethylphenidate may enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Dexmethylphenidate may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158413\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">High-fat meal may increase time to peak concentration. Management: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158394\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158405\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Dexmethylphenidate is the more active <i>d-thre</i>o-enantiomer of racemic methylphenidate; refer to Methylphenidate monograph for additional information</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1008325\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Evaluate patients for cardiac disease prior to initiation of therapy with thorough medical history, family history, and physical exam; consider ECG; perform ECG and echocardiogram if findings suggest cardiac disease; promptly conduct cardiac evaluation in patients who develop chest pain, unexplained syncope, or any other symptom of cardiac disease during treatment. Monitor CNS activity; CBC with differential, platelet count; blood pressure and heart rate (baseline following dose increases and periodically during treatment),  sleep, appetite, abnormal movements, height, weight, BMI, growth in children. Patients should be re-evaluated at appropriate intervals to assess continued need of the medication. Observe for signs/symptoms of aggression or hostility, or depression. Monitor for visual disturbances. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158387\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Dexmethylphenidate is the more active, <i>d-threo</i>-enantiomer, of racemic methylphenidate. It is a CNS stimulant; blocks the reuptake of norepinephrine and dopamine, and increases their release into the extraneuronal space.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158403\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Rapid, within 1 to 2 hours of an effective dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration of action: Immediate release: 3 to 5 hours; extended release: 9 to 12 hours (Dopheide 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Immediate release: Rapid; Extended release: Bimodal (with 2 peak concentrations ~4 hours apart)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 2.65 &plusmn; 1.11 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Unknown; racemic methylphenidate: 12% to 15% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Via de-esterification to inactive metabolite, <i>d</i>-&alpha;-phenyl-piperidine acetate (<i>d</i>-ritalinic acid) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 22% to 25%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: 2 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 2 to 4.5 hours; <b>Note:</b> A few subjects displayed a half-life between 5 to 7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Fasting:  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Immediate release: 1 to 1.5 hours; after a high-fat meal: 2.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Extended release:  First peak: 1.5 hours (range: 1 to 4 hours); Second peak: 6.5 hours (range: 4.5 to 7 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (90%, primarily as inactive metabolite) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15597938\" class=\"nested sp-pop-child-nested drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Children showed somewhat lower AUCs after administration of dexmethylphenidate immediate release.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1008329\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Treatment with dexmethylphenidate should include &ldquo;drug holidays&rdquo; or periodic discontinuation in order to assess the patient's requirements, decrease tolerance, and limit suppression of linear growth and weight. Medications used to treat ADHD should be part of a total treatment program that may include other components such as psychological, educational, and social measures. Long-term use of the immediate release tablets (ie, &gt;6 weeks) and extended release capsules (&gt;7 weeks) has not been studied; long-term usefulness should be periodically re-evaluated for the individual patient. </p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">Focalin&reg; XR capsules use a bimodal release where <sup>1</sup>/<sub>2</sub> the dose is provided in immediate release beads and <sup>1</sup>/<sub>2</sub> the dose is in delayed release beads. A single, once-daily dose of a capsule provides the same amount of dexmethylphenidate as two tablets given 4 hours apart. The modified release properties of Focalin&reg; XR capsules are pH dependent; thus, concomitant administration of antacids or acid suppressants might alter the release of dexmethylphenidate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5989308\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Dexmethylphenidate HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $780.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $909.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $740.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $935.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $1,172.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $712.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">35 mg (100): $1,231.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $816.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Focalin XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $1,435.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $1,457.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $1,498.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $1,498.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $1,573.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $1,443.59</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">35 mg (100): $1,652.27</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $1,652.27</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Dexmethylphenidate HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (100): $68.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $97.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $140.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Focalin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (100): $75.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $108.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $155.65</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49939447\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Focalin (CH);</li>\n      <li>Neoaradix (CL)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, &quot;ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents,&quot; <i>Pediatrics</i>, 2011, 128(5):1007-22.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD; available at: http://americanheart.mediaroon.com/index.php?s=43&amp;item=422.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper WO, Habel LA, Sox CM, et al, &quot;ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults,&quot; <i>N Engl J Med</i>, 2011, 365(20):1896-904.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmethylphenidate-pediatric-drug-information/abstract-text/22043968/pubmed\" target=\"_blank\" id=\"22043968\">22043968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dopheide JA and Pliszka SR, &quot;Attention-Deficit-Hyperactivity Disorder: An Update,&quot; <i>Pharmacotherapy</i>, 2009, 29(6):656-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmethylphenidate-pediatric-drug-information/abstract-text/19476419/pubmed\" target=\"_blank\" id=\"19476419\">19476419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gelperin K, &quot;Cardiovascular Risk With Drug Treatments of ADHD,&quot; available at: http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4210s-index.htm. Accessed May 25, 2006.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gelperin K, &quot;Psychiatric Adverse Events With Drug Treatments of ADHD,&quot; available at: http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4210s-index.htm. Accessed May 25, 2006.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould MS, Walsh BT, Munfakh JL, et al, &quot;Sudden Death and Use of Stimulant Medications in Youths,&quot; <i>Am J Psychiatry</i>, 2009, 166(9):992-1001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmethylphenidate-pediatric-drug-information/abstract-text/19528194/pubmed\" target=\"_blank\" id=\"19528194\">19528194</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenhill LL, Muniz R, Ball RR, et al, &quot;Efficacy and Safety of Dexmethylphenidate Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 2006, 45(7):817-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmethylphenidate-pediatric-drug-information/abstract-text/16832318/pubmed\" target=\"_blank\" id=\"16832318\">16832318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harstad EB, Weaver AL, Katusic SK, et al. ADHD, stimulant treatment, and growth: a longitudinal study. <i>Pediatrics</i>. 2014;134(4):e935-944.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmethylphenidate-pediatric-drug-information/abstract-text/25180281 /pubmed\" target=\"_blank\" id=\"25180281 \">25180281 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howard JT, Walick KS, Rivera JC. Preliminary evidence of an association between ADHD medications and diminished bone health in children and adolescents.<i> J Pediatr Orthop</i>. 2015 Sep 20. [Epub ahead of print]<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmethylphenidate-pediatric-drug-information/abstract-text/26398435 /pubmed\" target=\"_blank\" id=\"26398435 \">26398435 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;National Institute of Mental Health Multimodal Treatment Study of ADHD Follow-Up: Changes in Effectiveness and Growth After the End of Treatment,&quot; <i>Pediatrics</i>, 2004, 113(4):762-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmethylphenidate-pediatric-drug-information/abstract-text/15060225/pubmed\" target=\"_blank\" id=\"15060225\">15060225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nissen SE, &ldquo;ADHD Drugs and Cardiovascular Risk,&rdquo; <i>New Eng J Med</i>, 2006, 354(14):1445-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmethylphenidate-pediatric-drug-information/abstract-text/16549404/pubmed\" target=\"_blank\" id=\"16549404\">16549404</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pliszka S and AACAP Work Group on Quality Issues, &quot;Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 2007, 46(7):894-921.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmethylphenidate-pediatric-drug-information/abstract-text/17581453/pubmed\" target=\"_blank\" id=\"17581453\">17581453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poulton A, &quot;Growth on Stimulant Medication; Clarifying the Confusion: A Review,&quot; <i>Arch Dis Child</i>, 2005, 90(8):801-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmethylphenidate-pediatric-drug-information/abstract-text/16040876/pubmed\" target=\"_blank\" id=\"16040876\">16040876</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poulton AS, Bui Q, Melzer E, Evans R. Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder: a prospective cohort study. <i>Int Clin Psychopharmacol</i>. 2016;31(2):93-99. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmethylphenidate-pediatric-drug-information/abstract-text/26544899 /pubmed\" target=\"_blank\" id=\"26544899 \">26544899 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prince JB, &quot;Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Children and Adolescents: Update on New Stimulant Preparations, Atomoxetine, and Novel Treatments,&quot; <i>Child Adolesc Psych Clin N Am</i>, 2006, 15(1):13-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmethylphenidate-pediatric-drug-information/abstract-text/16321724/pubmed\" target=\"_blank\" id=\"16321724\">16321724</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson DM and Keating GM, &quot;Dexmethylphenidate Extended Release: In Attention-Deficit Hyperactivity Disorder,&quot; <i>Drugs</i>, 2006, 66(5):661-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmethylphenidate-pediatric-drug-information/abstract-text/16620143/pubmed\" target=\"_blank\" id=\"16620143\">16620143</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silva RR, Muniz R, Pestreich L, et al, &quot;Dexmethylphenidate Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 2008, 47(2):199-208.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmethylphenidate-pediatric-drug-information/abstract-text/18176337/pubmed\" target=\"_blank\" id=\"18176337\">18176337</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silva RR, Muniz R, Pestreich L, et al, &quot;Efficacy and Duration of Effect of Extended-Release Dexmethylphenidate Versus Placebo in Schoolchildren With Attention-Deficit/Hyperactivity Disorder,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2006, 16(3):239-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmethylphenidate-pediatric-drug-information/abstract-text/16768632/pubmed\" target=\"_blank\" id=\"16768632\">16768632</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vetter VL, Elia J, Erickson C, et al, &quot;Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,&quot; <i>Circulation</i>, 2008, 117(18):2407-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmethylphenidate-pediatric-drug-information/abstract-text/18427125/pubmed\" target=\"_blank\" id=\"18427125\">18427125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilens TE, &quot;Mechanism of Action of Agents Used in Attention-deficit Hyperactivity Disorder,&quot; <i>J Clin Psychiatry</i>, 2006, 67(suppl 8):32-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmethylphenidate-pediatric-drug-information/abstract-text/16961428/pubmed\" target=\"_blank\" id=\"16961428\">16961428</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13010 Version 153.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708694\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F158416\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1008289\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1008319\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F158399\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F158384\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F158431\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874426\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1008323\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F158412\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1008290\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5707763\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F158434\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F158404\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F158388\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25855841\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299158\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F158392\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F158413\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F158394\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F158405\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1008325\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F158387\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F158403\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Pediatric Considerations\" href=\"#F15597938\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1008329\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5989308\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49939447\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13010|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dexmethylphenidate-drug-information\" class=\"drug drug_general\">Dexmethylphenidate: Drug information</a></li><li><a href=\"topic.htm?path=dexmethylphenidate-patient-drug-information\" class=\"drug drug_patient\">Dexmethylphenidate: Patient drug information</a></li></ul></div></div>","javascript":null}